Perio drug reduces risk of osteoporosis, heart disease
A drug approved by the U.S. Food and Drug Administration (FDA) for treating periodontal disease could also significantly reduce the risk of osteoporosis and cardiovascular disease in postmenopausal women, according to a study in the Journal of the American Dental Association (March 2011, Vol. 142:3, pp. 262-273). Subantimicrobial-dose doxycycline (SDD) is the only drug approved by the FDA for treating chronic inflammatory periodontal disease. For the study, researchers from several

